Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Branch Retinal Vein Occlusion

Branch retinal vein occlusion.

Retinal vein occlusions (RVO) are the second commonest sight threatening vascular disorder. Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) are the two basic types of vein occlusion. Branch retinal vein occlusion is three times more common than central retinal vein occlusion and- second only to diabetic retinopathy as the most common retinal vascular cause of visu...

Branch Retinal Vein Occlusion followed by Central Retinal Vein Occlusion

A 59-year-old woman with history of noninsulin dependent diabetes mellitus and systemic hypertension presented with decreased vision in her left eye since 2 months ago. Bestcorrected visual acuity (BCVA) was 20/20 and 20/400 in the right and left eyes respectively. Relative afferent pupillary defect was negative. Anterior segment examination was unremarkable except for mild posterior subcapsula...

Experimental branch retinal vein occlusion.

Evaluation of Optical Coherence Tomography Angiography Findings in Patients with Branch Retinal Vein Occlusion

Purpose: To analyze the correlation of optical coherence tomography angiography (OCTA) findings with visual acuity (VA) in patients with branch retinal vein occlusion (BRVO). Methods: This cross-sectional study was performed on 20 eyes of 20 patients with unilateral BRVO involving the macula referred to the ophthalmology clinic of Rassoul Akram Hospital. OCTA imaging was conducted for all patie...

Outcomes of Intravitreal bevacizumab in patients with acute branch retinal vein occlusion

Introduction: The study aimed to evaluate the long-term effects of intravitreal bevacizumab on macular edema and visual acuity in patients with Acute branch Retinal Vein Occlusion (BRVO) that had not received any treatment. Methods: 22 patients in first week of BRVO onset that was diagnosed with flurcein angiography were treated with intravitreal injection of 1.25 mg bevacizumab. Macular thicke...